Table 2 Most frequently used medications for EIBA and EIBwA and the 2015 World Anti-Doping Agency (WADA) regulations
From: Exercise-induced bronchoconstriction: new evidence in pathogenesis, diagnosis and treatment
Treatment | WADA rules | Notes |
|---|---|---|
Antihistamines | Permitted | Second generation molecules should be preferred to avoid side effects |
Leukotriene modifiers | Permitted | |
Inhaled steroids | Permitted | |
Systemic steroids | Prohibited in competition | |
Beta-2 agonists | Inhaled Salbutamol (max 1600 mcg/24H), Formoterol (max 54 mcg/24H) and Salmeterol permitted | The presence in urine of salbutamol >1000 ng/mL or formoterol >40 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding |
All others prohibited in and out | ||
competition | ||
Mast-cell stabilizers | Permitted | |
Anticholinergic agents | Permitted | |
Immunotherapy | Permitted | SCIT should not be performed before or after physical exercise |